Recent events
Recent events tied to this brand in public sources.
Back to profile11 entries
2022
FDA approves Jardiance for adults with heart failure
The FDA approved Boehringer Ingelheim's drug Jardiance, co-developed with Eli Lilly, to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults.
2022
Boehringer Ingelheim sues Laurus over Jardiance patent
Boehringer Ingelheim Pharmaceuticals and related entities filed a lawsuit against Laurus Labs and Laurus Generics in Delaware, alleging patent infringement related to a generic version of Jardiance and seeking injunctive relief and monetary damages.
2021
Boehringer Ingelheim acquires Abexxa Biologics
Boehringer Ingelheim acquired Abexxa Biologics. The deal includes an undisclosed upfront payment, milestones and other payments; financial details were not disclosed.
2021
Boehringer Ingelheim announces acquisition of Abexxa Biologics
Boehringer Ingelheim announced that it had acquired Abexxa Biologics, a biopharmaceutical company focused on immuno-oncology and oncology research. The acquisition gives Boehringer Ingelheim access to Abexxa’s expertise in targeting cancer-specific proteins inside cells.
2021
ImaginAb and Boehringer Ingelheim sign license and supply agreement
ImaginAb announced that it signed a new multi-year, non-exclusive license agreement with Boehringer Ingelheim. Under the agreement, ImaginAb will supply clinical doses of its 89Zr CD8 ImmunoPET technology for use in clinical development of Boehringer Ingelheim oncology therapeutics in North America and Europe.
2021
WEHI and Boehringer Ingelheim establish cancer drug research partnership
WEHI and Boehringer Ingelheim established a three-year research collaboration to discover and develop anti-cancer therapeutics using targeted protein degradation.
2021
Elsevier releases updated DDIRC 2.0 in PharmaPendium
Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.
2021
Boehringer Ingelheim appoints Vani Manja as India Country Managing Director
Boehringer Ingelheim appointed Vani Manja as Country Managing Director for India, effective January 1, 2021. She also joined the company’s Board.
2020
Boehringer Ingelheim announces acquisition of Northern Biologics
Boehringer Ingelheim announced its acquisition of Northern Biologics Inc. The seller will retain the Northern Biologics name and continue certain preclinical work on one program, while Boehringer Ingelheim will lead clinical, regulatory and commercial development of the acquired programs.
2020
Boehringer Ingelheim and Carebox launch MyStudyWindow
Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow, a digital platform providing information about Boehringer Ingelheim studies and helping users identify potentially relevant clinical trials.
2019
Genedata and Boehringer Ingelheim expand collaboration
Genedata announced an expansion of its collaboration with Boehringer Ingelheim to digitalize and automate cell line development processes. Genedata Selector was deployed as part of the collaboration.